Breadcrumb
  1. Home
  2. 340B Drug Pricing Program
  3. Program Integrity
  4. FY 2016 Manufacturer Audit Results

FY 2016 Manufacturer Audit Results

Updated 9/11/18. The results chart includes audits where the findings have been finalized. Remaining audits are still under review. Information on Corrective Action Plans and Sanctions will be updated once approved by HRSA. HRSA recommends covered entities do not contact audited manufacturers regarding sanctions until a corrective action plan has been approved by HRSA and posted on this website.

Results posted for 5 audits.
Manufacturer Sort descending Labeler Codes Reviewed State OPA Findings Sanction Corrective Action Status
Celgene 46026
59572
68817
67211
NJ

No adverse findings

None

N/A

Fresenius Kabi 63323
76045
IL

No adverse findings

None

N/A

Hospira, Inc. 00409
61703
IL

No adverse findings

None

N/A

Leading Pharma, LLC 64125
69315
NJ

No adverse findings

None

N/A

Valeant Pharmaceuticals, Inc. 00024
00066
00095
00187
00884
13548
24208
25010
30237
42702
57782
62592
62856
64455
65649
66490
67425
68012
68682
68782
99207
NJ

No adverse findings

None

N/A

Date Last Reviewed: